Immutep Ltd (AU:IMM) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep Ltd has unveiled promising Phase II trial results for its novel combination therapy involving eftilagimod alpha, pembrolizumab, and radiotherapy in treating soft tissue sarcoma. The trial demonstrated a significant increase in tumor hyalinization, suggesting improved outcomes and survival rates for patients. With over 71% of participants showing a pathologic response, the therapy showcases potential in addressing this challenging cancer type.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.